Journal of Cancer · 2019 · 54 citations · 33 references
MedicineOncologySurgeryChemotherapyGastrointestinal OncologySurgical OncologyAdjuvant ChemotherapyCancer BiomarkersCancer StagingCancer Survival AnalysisColorectal CancerPrognostic AssessmentCancer Antigen 19-9Colorectal Cancer PrognosisDisease-free Survival AnalysisPrognostic Factors AnalysisPrognostic Marker AssessmentPrognostic PredictionPrognostic Tumor MarkersPrognostic Variables
Carbohydrate antigen 19-9 (CA19-9) is one of the most widely used tumor markers in gastrointestinal cancer. However, serum CA19-9 is not a recommended routine measurement in colon cancer. In this study, we evaluated the value of the preoperative serum CA19-9 level for the prediction of postoperative prognosis in stage III colon cancer. The medical records of 367 consecutive patients with stage III colon cancer who underwent curative resection followed by adjuvant chemotherapy with oxaliplatin and capecitabine between December 2007 and April 2015 were retrospectively reviewed. We determined the optimal cutoff value of CA19-9 for 3-year recurrence using the receiver operating characteristic (ROC) method. Differences in disease-free survival (DFS) and overall survival (OS) rates stratified by CA19-9 level were compared by using Kaplan-Meier and log-rank tests. A Cox proportional hazards model was used to identify prognostic variables for DFS and OS. The statistically determined best cutoff value for CA19-9 was 24 U/ml. High CA19-9 levels (> 24 U/ml) were significantly associated with poorly differentiated tumors, abnormal carcinoembryonic antigen (CEA) levels, and a high cumulative incidence of lung metastasis. Additionally, compared with low CA19-9 levels, high preoperative CA19-9 levels were associated with inferior 3-year DFS and OS rates, especially for high-risk patients (T4Nany or TanyN2). Multivariate analyses revealed that CA19-9 was an independent factor associated with both DFS (hazard ratio [HR], 2.248; 95% confidence interval [CI], 1.393-3.628; P = 0.001) and OS (HR: 2.081; 95% CI: 1.137-3.808; P = 0.017). The results of this study showed that high levels of preoperative serum CA19-9 indicated a worse prognostic outcome for stage III colon cancer patients. An early follow-up protocol to assess lung metastasis and a full course of adjuvant chemotherapy should be used for these patients.
33
Cancer statistics in China, 2015
Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians · 2016 · 18K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text
Colorectal cancer statistics, 2017
Rebecca L. Siegel, Kimberly D. Miller, Stacey A. Fedewa et al. · CA A Cancer Journal for Clinicians · 2017 · 3.9K citations · Full text
Colorectal cancer statistics, 2023
Rebecca L. Siegel, Nikita Sandeep Wagle, Andrea Cercek et al. · CA A Cancer Journal for Clinicians · 2023 · 3.8K citations · Full text
Advances in Experimental Medicine and Biology
G.G. Lunt · Neurochemistry International · 1986 · 1.9K citations